This study is about testing a new heart medicine called Baxdrostat with another medicine called Dapagliflozin. It is for people aged 40 and older who have Type 2 Diabetes (T2DM), heart or blood vessel disease, and high blood pressure (HTN). People must also have a safe level of potassium in their blood. Potassium is important for heart and muscle function. The study will start with a screening phase of up to 14 days. If you qualify, you may take Dapagliflozin for 4-6 weeks before the main part of the study.

Once the study begins, you will visit the study site at 2, 4, 8, 16, and 34 weeks, and then every 4 months. If you stop the study drug early, you can still stay in the study. The study will continue until a certain number of heart-related problems or deaths occur.

• The study involves site visits and a run-in period with Dapagliflozin.
• No consent is needed for the optional pre-screening.
• Participants can remain in the study even if they stop one of the drugs early.